Albanell-Fernandez M, Rodriguez-Reyes M, Bastida C, Soy D
Clin Pharmacokinet. 2025; 64(1):1-25.
PMID: 39821208
PMC: 11762427.
DOI: 10.1007/s40262-024-01459-z.
van Valkengoed D, Krekels E, Knibbe C
Clin Pharmacokinet. 2024; 64(2):173-192.
PMID: 39644458
PMC: 11782306.
DOI: 10.1007/s40262-024-01444-6.
Zou P, Atluri A, Chang P, Goedecke M, Leil T
CPT Pharmacometrics Syst Pharmacol. 2024; 14(1):118-129.
PMID: 39526427
PMC: 11706424.
DOI: 10.1002/psp4.13248.
Li S, Ye X, Wang Q, Cheng Z, Liu F, Xie F
CPT Pharmacometrics Syst Pharmacol. 2024; 14(1):152-163.
PMID: 39403008
PMC: 11706418.
DOI: 10.1002/psp4.13254.
Boast A, Zhang W, Soeorg H, Gonis G, Di Carlo A, Daley A
Antimicrob Agents Chemother. 2024; 68(11):e0074724.
PMID: 39377581
PMC: 11539224.
DOI: 10.1128/aac.00747-24.
The impact of age and renal function on the pharmacokinetics and protein binding characteristics of fludarabine in paediatric and adult patients undergoing allogeneic haematopoietic stem cell transplantation conditioning.
Nath C, Rosser S, Nath K, Chung J, Larsen S, Gibson J
Eur J Clin Pharmacol. 2024; 80(12):1967-1987.
PMID: 39298000
PMC: 11557628.
DOI: 10.1007/s00228-024-03751-0.
Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model-based approach.
Yamaguchi D, Katsube T, Wajima T
Pharmacol Res Perspect. 2024; 12(5):e70001.
PMID: 39180172
PMC: 11343721.
DOI: 10.1002/prp2.70001.
Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.
Morales Junior R, Mizuno T, Paice K, Pavia K, Hambrick H, Tang P
J Antimicrob Chemother. 2024; 79(10):2668-2677.
PMID: 39092928
PMC: 11442002.
DOI: 10.1093/jac/dkae274.
Impact of fluid balance on beta-lactam antibiotics target attainment: Insights from a simulation-based meropenem study.
Morales Jr R, Mizuno T, Paice K, Hambrick H, Punt N, Tang Girdwood S
Int J Antimicrob Agents. 2024; 64(3):107267.
PMID: 38971204
PMC: 11488156.
DOI: 10.1016/j.ijantimicag.2024.107267.
Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
Maglalang P, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik C
Clin Pharmacokinet. 2024; 63(6):885-899.
PMID: 38814425
PMC: 11225543.
DOI: 10.1007/s40262-024-01367-2.
Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents.
OHanlon C, Sumpter A, Anderson B, Hannam J
Clin Pharmacokinet. 2024; 63(5):695-706.
PMID: 38613610
PMC: 11106138.
DOI: 10.1007/s40262-024-01372-5.
Covariate modeling in pharmacometrics: General points for consideration.
Sanghavi K, Ribbing J, Rogers J, Ahmed M, Karlsson M, Holford N
CPT Pharmacometrics Syst Pharmacol. 2024; 13(5):710-728.
PMID: 38566433
PMC: 11098153.
DOI: 10.1002/psp4.13115.
When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers?.
Wu Y, Allegaert K, Flint R, Goulooze S, Valitalo P, de Hoog M
Pharm Res. 2024; 41(4):637-649.
PMID: 38472610
PMC: 11024008.
DOI: 10.1007/s11095-024-03677-3.
Pediatric oncology drug development and dosage optimization.
Cheung S, Hay J, Lin Y, de Greef R, Bullock J
Front Oncol. 2024; 13:1235947.
PMID: 38348118
PMC: 10860405.
DOI: 10.3389/fonc.2023.1235947.
Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
White Y, P Solans B, Denti P, van der Laan L, Schaaf H, Vonasek B
Clin Infect Dis. 2024; 78(3):756-764.
PMID: 38340060
PMC: 10954342.
DOI: 10.1093/cid/ciae024.
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives.
Zhang W, Zhang Q, Cao Z, Zheng L, Hu W
Pharmaceutics. 2023; 15(12).
PMID: 38140105
PMC: 10747965.
DOI: 10.3390/pharmaceutics15122765.
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.
Dinh J, Johnson T, Grimstein M, Lewis T
Pharmaceutics. 2023; 15(11).
PMID: 38004559
PMC: 10675397.
DOI: 10.3390/pharmaceutics15112579.
Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan L, Garcia-Prats A, McIlleron H, Abdelwahab M, Winckler J, Draper H
Antimicrob Agents Chemother. 2023; 67(12):e0061123.
PMID: 37971239
PMC: 10720412.
DOI: 10.1128/aac.00611-23.
Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review.
Yang Y, Liu Z, Chen J, Wang X, Jiao Z, Wang Z
Eur J Clin Pharmacol. 2023; 80(1):11-37.
PMID: 37934204
DOI: 10.1007/s00228-023-03579-0.
Model-informed precision dosing in vancomycin treatment.
Yoon S, Guk J, Lee S, Chae D, Kim J, Park K
Front Pharmacol. 2023; 14:1252757.
PMID: 37876732
PMC: 10593454.
DOI: 10.3389/fphar.2023.1252757.